GA AND THE PRE-LESION
Often unexplored and unnoticed, the pre-lesion is the area just outside the lesion where complement overactivation is already causing the next wave of destruction. It’s also where your patients have the most to save.1-3
Explore new territory in GA
TREATMENT FOR GA
There is currently no FDA approved treatment for GA, yet it affects1,4,5
Five plus million people worldwide
About one million people in the United States
Learn more about the burden of GA on patients
Hear from a patient with GA

COMPLEMENT
OVERACTIVATION

may lead to lesion progression and loss of vision1,2,6,7

Explore the role of complement

HEAR FROM
YOUR PEERS

on lesion burden, progression, and the value of Fundus Autofluorescence (FAF)

Watch insights from a GA expert
Apellis is a global biopharmaceutical company that leverages courageous science and creativity. We are committed to addressing the unmet needs of patients and eye care professionals worldwide.

References: 1. Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37(5):819-835. doi:10.1097/iae.0000000000001392. 2. Katschke KJ Jr, Xi H, Cox C, et al. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy. Sci Rep. 2018;8(1):7348. doi:10.1038/s41598-018-25557-8. doi:10.1016/j.ophtha.2011.07.056. 3. Demirs JT, Yang J, Crowley MA, et al. Differential and altered spatial distribution of complement expression in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2021;62(7):26. doi:10.1167/iovs.62.7.26. 4. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116. doi:10.1016/S2214-109X(13)70145-1. 5. Friedman DS, O’Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572. doi:10.1001/archopht.122.4.564. 6. Park DH, Connor KM, Lambris JD. The challenges and promise of complement therapeutics for ocular diseases. Front Immunol. 2019;10:1007. doi:10.3389/fimmu.2019.01007. 7. Yates JRW, Sepp T, Matharu BK, et al; Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553-561. doi:10.1056/NEJMoa072618.